View details of this raise on Seedstage

Century City, CA

Developing groundbreaking therapies to improve treatment options for life-threatening diseases.

• Mission: Developing innovative therapies for life-threatening diseases such as cancer, Parkinson’s disease, and Acute Respiratory Distress Syndrome, prioritizing patient well-being.  
• Innovation: RP-323, a unique cell repair therapy that targets damaged cells while killing cancer cells, and enhances the immune system’s ability to fight cancer.  
• Clinical Progress: Demonstrated promising results in clinical trials, including high remission rates in Acute Myeloid Leukemia and tumor reduction in Hodgkin’s Lymphoma.  
• Safer Treatment Focus: Aiming to provide more effective and safer alternatives to traditional therapies, reducing harsh side effects commonly associated with cancer treatments.  
• Research & Development: Actively advancing clinical studies with partnerships to enhance capabilities and preparing for the next phase of drug trials.  
• Strategic Vision: Preparing for a go-public transaction to accelerate research and development, with the goal of transforming treatment landscapes for life-threatening diseases.  

PhorMed is focused on developing innovative therapies to combat life-threatening diseases such as cancer, Parkinson’s disease, and Acute Respiratory Distress Syndrome. The company is advancing its platform drug, RP-323, which employs a unique cell repair therapy to target and repair damaged cells while simultaneously killing cancer cells.

This approach not only addresses the underlying causes of these diseases but also aims to enhance the immune system’s ability to fight cancer. With clinical trials currently underway, PhorMed has demonstrated promising results, including high remission rates in Acute Myeloid Leukemia and tumor reduction in Hodgkin’s Lymphoma.

The company’s mission is to provide safer and more effective treatment options that prioritize patient well-being over harsh side effects commonly associated with traditional therapies. As PhorMed prepares for its go-public transaction, it seeks to attract investment to further its research and development efforts, ultimately aiming to transform the landscape of treatment for various life-threatening conditions and improve the quality of life for patients in need of viable alternatives.

Company Info

PhorMed is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases through clinical research and innovative therapies.

PhorMed is a biopharmaceutical company engaged in clinical research focused on developing treatments for various medical conditions, including Acute Respiratory Distress Syndrome (ARDS), cancer types such as Acute Myeloid Leukemia (AML) and Hodgkin’s Lymphoma, and Parkinson’s disease. The company is advancing its lead technology, RP-323, which is designed for cell repair and immunotherapy, aiming to reduce inflammation associated with these diseases. PhorMed is currently preparing to enter the next phase of clinical trials and has recently completed feasibility studies for its treatments. The company has established partnerships to enhance its research capabilities and has been involved in fundraising efforts to support its clinical studies. PhorMed is committed to ethical business practices and aims to contribute to advancements in drug research and development within the healthcare sector.